Sign in

Myelodysplastic syndromes: trials that stopped early

Trials on Myelodysplastic syndromes that stopped early, each with the reason the sponsor wrote in the registry, quoted word for word. Next to them: finished trials whose registry record links a result paper.

Stopped early

86 stopped trials give a reason in the registry, latest registry update first.

  1. Terminated

    A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

    Reason given in the registry

    “Change in corporate strategy”

    Quoted unchanged from ClinicalTrials.gov; record updated 7 Mar 2025.

    Ended
    Apr 2024
    Phase
    Phase 1
    Run by
    Aptose Biosciences Inc.
    Registry record
    NCT04477291
  2. Terminated

    Blood Samples to Identify Biomarkers of Busulfan

    Reason given in the registry

    “Study terminated due to end of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 3 Mar 2025.

    Ended
    Oct 2024
    Run by
    Fred Hutchinson Cancer Center
    Registry record
    NCT02291965
  3. Terminated

    JSP191 (briquilimab) in Subjects with LR-MDS

    Reason given in the registry

    “The study was terminated due to a lack of improvement in clinical efficacy outcomes.”

    Quoted unchanged from ClinicalTrials.gov; record updated 27 Feb 2025.

    Ended
    Oct 2024
    Phase
    Phase 1
    Run by
    Jasper Therapeutics, Inc.
    Registry record
    NCT05903274
  4. Terminated

    Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)

    Reason given in the registry

    “The sponsor is no longer supporting the drug”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 Dec 2024.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    Washington University School of Medicine
    Registry record
    NCT04582864
  5. Withdrawn

    Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT

    Reason given in the registry

    “Lack of funding”

    Quoted unchanged from ClinicalTrials.gov; record updated 5 Dec 2024.

    Ended
    Jun 2026
    Phase
    Phase 1
    Run by
    Leland Metheny
    Registry record
    NCT03939585
  6. Terminated

    Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant

    Reason given in the registry

    “Lack of Enrollment”

    Quoted unchanged from ClinicalTrials.gov; record updated 18 Nov 2024.

    Ended
    Dec 2023
    Phase
    Phase 1
    Run by
    Hackensack Meridian Health
    Registry record
    NCT02846376
  7. Withdrawn

    A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes

    Reason given in the registry

    “Sponsor decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 9 Oct 2024.

    Ended
    Mar 2025
    Run by
    Bristol-Myers Squibb
    Registry record
    NCT06581055
  8. Withdrawn

    Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

    Reason given in the registry

    “Withdrawn -ctms”

    Quoted unchanged from ClinicalTrials.gov; record updated 19 Sept 2024.

    Ended
    Feb 2026
    Phase
    Phase 1
    Run by
    City of Hope Medical Center
    Registry record
    NCT05823480
  9. Terminated

    Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

    Reason given in the registry

    “Prematurely according to trial protocol”

    Quoted unchanged from ClinicalTrials.gov; record updated 13 Aug 2024.

    Ended
    Jul 2024
    Phase
    Phase 2
    Run by
    University of Leipzig
    Registry record
    NCT05178342
  10. Withdrawn

    Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

    Reason given in the registry

    “Unable to accommodate FDA recommendations for protocol revisions”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Jun 2024.

    Phase
    Phase 2
    Run by
    Northside Hospital, Inc.
    Registry record
    NCT06337331
  11. Terminated

    Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

    Reason given in the registry

    “Slow recruitment. It is not considered likely that the CANFIRE trial will be able to reach the target number of patients. Clinical responders will be further treated within the trial (expected duration: 3 years after stop of enrollment).”

    Quoted unchanged from ClinicalTrials.gov; record updated 6 May 2024.

    Ended
    Feb 2024
    Phase
    Phase 2
    Run by
    University of Leipzig
    Registry record
    NCT05237713
  12. Withdrawn

    High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

    Reason given in the registry

    “PI has left IU with no plan to initiate study at IU”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Apr 2024.

    Ended
    Dec 2025
    Phase
    Phase 1/2
    Run by
    Indiana University
    Registry record
    NCT05895201
  13. Withdrawn

    A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

    Reason given in the registry

    “waiting for update from Study Lead”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Apr 2024.

    Phase
    Phase 1/2
    Run by
    Novartis Pharmaceuticals
    Registry record
    NCT05367401
  14. Terminated

    A Study of H3B-8800 (RVT-2001) in Participants With Lower Risk Myelodysplastic Syndromes

    Reason given in the registry

    “The study was terminated after conducting an interim analysis of the available data where it became evident that the observed efficacy results were not in alignment with the initially set expectations.”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Feb 2024.

    Ended
    Feb 2024
    Phase
    Phase 1
    Run by
    Hemavant Sciences GmbH
    Registry record
    NCT02841540
  15. Withdrawn

    Magrolimab Plus Intensive Chemotherapy in Newly Diagnosed AML or HR-MDS

    Reason given in the registry

    “Trial was stopped prematurely due to safety reasons”

    Quoted unchanged from ClinicalTrials.gov; record updated 12 Feb 2024.

    Phase
    Phase 2
    Run by
    Uwe Platzbecker
    Registry record
    NCT05829434
  16. Suspended

    A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)

    Reason given in the registry

    “Slow enrollment and financial limitations”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Feb 2024.

    Ended
    Dec 2024
    Phase
    Phase 1/2
    Run by
    Cyclacel Pharmaceuticals, Inc.
    Registry record
    NCT05168904
  17. Terminated

    PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

    Reason given in the registry

    “Company Decision”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Jan 2024.

    Ended
    Jan 2024
    Phase
    Phase 1
    Run by
    Prelude Therapeutics Incorporated
    Registry record
    NCT05107856
  18. Withdrawn

    A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies

    Reason given in the registry

    “insufficient staff and updates in standard practice have made it difficult to recruit participants”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Dec 2023.

    Phase
    Phase 1/2
    Run by
    Naoyuki G. Saito, M.D., Ph.D.
    Registry record
    NCT05201183
  19. Withdrawn

    A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

    Reason given in the registry

    “Despite several attempts to recruit eligible participants and major protocol amendments to increase the recruitment rate, recruitment challenges remained. Therefore, the Sponsor has made the decision to terminate the KER047-IR-202 Study globally.”

    Quoted unchanged from ClinicalTrials.gov; record updated 24 Nov 2023.

    Ended
    Jan 2026
    Phase
    Phase 2
    Run by
    Keros Therapeutics, Inc.
    Registry record
    NCT05927012
  20. Suspended

    Safety and Efficacy of IBI188 With Azacitidine in Subjects With Newly Diagnosed Higher Risk MDS

    Reason given in the registry

    “Suspended for changes in development strategy”

    Quoted unchanged from ClinicalTrials.gov; record updated 16 Feb 2023.

    Ended
    Aug 2024
    Phase
    Phase 1
    Run by
    Innovent Biologics (Suzhou) Co. Ltd.
    Registry record
    NCT04485065
  21. Withdrawn

    Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RP7214 in Combination With Azacitidine in Patients With Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia

    Reason given in the registry

    “Change in development plan”

    Quoted unchanged from ClinicalTrials.gov; record updated 31 Oct 2022.

    Ended
    Nov 2025
    Phase
    Phase 1/2
    Run by
    Rhizen Pharmaceuticals SA
    Registry record
    NCT05246384
  22. Withdrawn

    A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

    Reason given in the registry

    “The cusatuzumab MDS strategy is under revision”

    Quoted unchanged from ClinicalTrials.gov; record updated 20 May 2022.

    Ended
    Jan 2025
    Phase
    Phase 2
    Run by
    Janssen Research & Development, LLC
    Registry record
    NCT04264806
  23. Withdrawn

    Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

    Reason given in the registry

    “No funding support”

    Quoted unchanged from ClinicalTrials.gov; record updated 11 Mar 2022.

    Ended
    Dec 2024
    Phase
    Phase 2
    Run by
    Washington University School of Medicine
    Registry record
    NCT04893915
  24. Withdrawn

    HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

    Reason given in the registry

    “Medigene transfered all rights to a new Sponsor”

    Quoted unchanged from ClinicalTrials.gov; record updated 8 Oct 2021.

    Ended
    Jul 2025
    Phase
    Phase 1
    Run by
    Medigene AG
    Registry record
    NCT04464889
  25. Withdrawn

    A Study of Pevonedistat Combined With Decitabine and Cedazuridine in Adults With Higher-risk Myelodysplastic Syndromes

    Reason given in the registry

    “Sponsor Decision to Terminate Trial”

    Quoted unchanged from ClinicalTrials.gov; record updated 29 Sept 2021.

    Ended
    Nov 2024
    Phase
    Phase 2
    Run by
    Takeda
    Registry record
    NCT04985656
  26. Withdrawn

    CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome

    Reason given in the registry

    “Administrative withdrawal by IRB”

    Quoted unchanged from ClinicalTrials.gov; record updated 14 Apr 2021.

    Phase
    Phase 1/2
    Run by
    Wake Forest University Health Sciences
    Registry record
    NCT03929211

Sources: ClinicalTrials.gov and the EU Clinical Trials Register. Status, reason, dates and result links are registry fields, shown as the registry gives them.